SEHK:2256Biotechs
Assessing Abbisko Cayman (SEHK:2256) Valuation After FDA Acceptance Of Pimicotinib NDA
Abbisko Cayman (SEHK:2256) is back in focus after the U.S. FDA formally accepted the New Drug Application for pimicotinib, its oral CSF-1R inhibitor for tenosynovial giant cell tumor, following positive Phase III MANEUVER trial results.
See our latest analysis for Abbisko Cayman.
Investors appear to be weighing the FDA’s NDA acceptance against earlier gains, with a 1-month share price return of 7.85% and year to date share price return of 9.68%, while the 1-year total shareholder return is...